Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Department of Medicine & Surgery, University of Parma, Parma, Italy.
Immunotherapy. 2020 Feb;12(2):151-159. doi: 10.2217/imt-2019-0180.
INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. We reported the final OS analysis from the original study population and within subgroups. Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.
INVIDIa 是一项回顾性、多中心研究，旨在探讨流感疫苗在 300 名接受免疫治疗的癌症患者中的临床疗效。最初报告时，总生存（OS）尚未成熟。我们报告了原始研究人群和亚组内的最终 OS 分析。在单因素和多因素分析中，流感综合征（IS）的发生与总体人群的更好 OS 显著相关（OR：0.53 [95% CI：0.32-0.88]；p = 0.01）。在肺癌亚组中，接种流感疫苗和/或发生 IS 与更好的 OS 相关（p = 0.04）。在老年患者中，流感疫苗是相对 OS 优势的主要变量（p = 0.05）。在 INVIDIa 人群中，接种流感疫苗和/或发生 IS 与更好的 OS 相关。
